Gossamer Bio, Inc. (GOSS) Q4 2020 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by and welcome to the Gossamer Bio Q4 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. I would now like to hand the conference over to your speaker today, Brian Jurado. Please go ahead, sir. Thank you, operator, and thank you all for joining us this morning. I am joined on today's call by Gossamer's co-founder, chairman, executive officer, Faheem Hasnain, and Gossamer's senior vice president of clinical development, Richard Aranda. Earlier this morning, Gossamer Bio issued a press release announcing it's year-end 2020 financial results and provided a corporate update. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Gossamer management will be making forward-looking statements. Actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the statements contained in Gossamer's news releases, SEC filings, including in the annual report on Form 10-K and subsequent filings. This conference call also contains time-sensitive information that may be accurate for only a limited period of time. Gossamer Bio takes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. Now I'd like to turn the call over to Saheem. Saheem? Thank you, Brian, and thanks to a...